newsfilter
← Latest News
GlobeNewswire·

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic